© 2016

Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology


Part of the SpringerBriefs in Immunology book series (BRIEFSIMMUN)

Table of contents

  1. Front Matter
    Pages i-vii
  2. Radoslaw Zagozdzon, Witold Lasek
    Pages 1-19
  3. Witold Lasek, Marek Jakóbisiak
    Pages 21-41
  4. Witold Lasek, Radoslaw Zagozdzon
    Pages 43-75

About this book


This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).


Interleukin 12 Antitumor Effects Cancer Immunotherapy Clinical Trials

Authors and affiliations

  1. 1.Department of Immunology, Centre for Biostructure ResearchMedical University of WarsawWarsawPoland
  2. 2.Department of ImmunologyMedical University of WarsawWarsawPoland

Bibliographic information

Industry Sectors
Health & Hospitals